Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

05 déc. 2025 08h30 HE | Source: Lexicon Pharmaceuticals, Inc.

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with...
08 nov. 2025 14h30 HE | Source: Lexicon Pharmaceuticals, Inc.

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific...
06 nov. 2025 07h30 HE | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Lexicon Pharmaceuticals reported third quarter 2025 financial results and provided an update on key corporate milestones and accomplishments.
08 avr. 2024 11h15 HE | Source: Imbria Pharmaceuticals Inc.

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

– Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated – – Results support initiation of the Phase 3 FORTITUDE-HCM...
14 nov. 2023 13h00 HE | Source: DelveInsight Business Research LLP

Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics, Bristol-Myers Squibb, Imbria Pharmaceuticals, Inc., Tenaya Therapeutics, Novartis

New York, USA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Hypertrophic Cardiomyopathy Treatment Market to Exhibit Impressive Growth by 2023, Predicts DelveInsight | Key Companies - Cytokinetics,...
22 juin 2023 09h54 HE | Source: Growth Plus Reports

Hypertrophic Cardiomyopathy Market to Hit US$ 1.35 Billion by 2031| Exclusive Report by Growth Plus Reports

Newark, New Castle, USA, June 22, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for hypertrophic cardiomyopathy in 2022 to be worth US$ 1.12 billion, and it is...
17 mai 2023 08h00 HE | Source: Imbria Pharmaceuticals Inc.

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect

BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
05 déc. 2022 08h00 HE | Source: Imbria Pharmaceuticals Inc.

Ninerafaxstat Showcased at the 19th Annual Global Cardio Vascular Clinical Trialists (CVCT) Forum with Focus on the Potential in Non-obstructive Hypertrophic Cardiomyopathy

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
02 avr. 2020 11h50 HE | Source: Reports and Data

Hypertrophic Cardiomyopathy Therapeutics Market To Reach USD 1.42 Billion By 2027 | Reports and Data

New York, April 02, 2020 (GLOBE NEWSWIRE) -- According to the current analysis of Reports and Data, the global Hypertrophic Cardiomyopathy Therapeutics Market valued at USD 1.20 Billion in 2019 and...
04 nov. 2019 08h30 HE | Source: MyoKardia, Inc.

MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...

Page suivante